107 related articles for article (PubMed ID: 2345069)
21. Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
Saiers JH; Blumenstein B; Slavik M; Costanzi JH; Crawford ED
Cancer Treat Rep; 1987 Dec; 71(12):1305-6. PubMed ID: 3690546
[No Abstract] [Full Text] [Related]
22. Phase II trial of spirogermanium and vindesine in malignant glioma.
Alavi JB; Schoenfeld D; Skeel RT; Kirkwood R; Tsung L; Marsh JC
Am J Clin Oncol; 1989 Feb; 12(1):8-10. PubMed ID: 2912024
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of spirogermanium in the treatment of metastatic breast cancer.
Pinnamaneni K; Yap HY; Legha SS; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1984 Sep; 68(9):1197-8. PubMed ID: 6478457
[No Abstract] [Full Text] [Related]
24. Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
Budman DR; Ginsberg S; Perry M; Weinberg V; Schein P; Hanson J; Coleman M; Wood W
Cancer Treat Rep; 1982 Aug; 66(8):1667-8. PubMed ID: 7105058
[No Abstract] [Full Text] [Related]
25. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of spirogermanium for treatment of advanced breast cancer.
Falkson G; Falkson HC
Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
[No Abstract] [Full Text] [Related]
27. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity.
Slavik M; Blanc O; Davis J
Invest New Drugs; 1983; 1(3):225-34. PubMed ID: 6678870
[TBL] [Abstract][Full Text] [Related]
28. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Asbury RF; Cnaan A; Johnson L; Harris J; Zaentz SD; Haller DG
Am J Clin Oncol; 1994 Apr; 17(2):166-9. PubMed ID: 8141110
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
Schulman P; Davis RB; Rafla S; Green M; Henderson E
Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
[No Abstract] [Full Text] [Related]
30. Phase I clinical trial of spirogermanium.
Schein PS; Slavik M; Smythe T; Hoth D; Smith F; Macdonald JS; Woolley PV
Cancer Treat Rep; 1980; 64(10-11):1051-6. PubMed ID: 7459890
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
Dhingra HM; Umsawasdi T; Chiuten DF; Murphy WK; Holoye PY; Spitzer G; Valdivieso M
Cancer Treat Rep; 1986 May; 70(5):673-4. PubMed ID: 3708617
[No Abstract] [Full Text] [Related]
32. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Novik Y; Ryan LM; Haller DG; Asbury R; Dutcher JP; Schutt A
Med Oncol; 1999 Dec; 16(4):261-6. PubMed ID: 10618689
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of spirogermanium in patients with advanced carcinoma of the cervix.
Brenner DE; Rosenshein NB; Dillon M; Jones HW; Forastiere A; Tipping S; Burnett LS; Greco FA; Wiernik PH
Cancer Treat Rep; 1985 Apr; 69(4):457-8. PubMed ID: 3995514
[No Abstract] [Full Text] [Related]
34. Pulmonary toxicity associated with spirogermanium.
Dixon C; Hagemeister F; Legha S; Bodey G
Cancer Treat Rep; 1984 Jun; 68(6):907-8. PubMed ID: 6733705
[No Abstract] [Full Text] [Related]
35. Therapy for advanced renal cell cancer with spirogermanium: a Southwest Oncology Group Study.
Saiers JH; Slavik M; Stephens RL; Crawford ED
Cancer Treat Rep; 1987 Feb; 71(2):207-8. PubMed ID: 3802117
[No Abstract] [Full Text] [Related]
36. Phase II study of spirogermanium in advanced breast cancer.
Kuebler JP; Tormey DC; Harper GR; Chang YC; Khandekar JD; Falkson G
Cancer Treat Rep; 1984 Dec; 68(12):1515-6. PubMed ID: 6509457
[No Abstract] [Full Text] [Related]
37. Phase II trial of spirogermanium in central nervous system tumors: a Southwest Oncology Group Study.
Goodwin JW; Crowley J; Tranum B; Vance R; Slavik M; Balcerzak S; Hacker D
Cancer Treat Rep; 1987 Jan; 71(1):99-100. PubMed ID: 3791276
[No Abstract] [Full Text] [Related]
38. An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma.
McMaster ML; Greco FA; Johnson DH; Hainsworth JD
Invest New Drugs; 1990 Feb; 8(1):87-92. PubMed ID: 2345074
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of spirogermanium in metastatic prostate cancer.
Dexeus FH; Logothetis C; Samuels ML; Hossan B
Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
[No Abstract] [Full Text] [Related]
40. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
